NCT05826964 2026-01-13Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast CancerUniversity of MiamiPhase 2 Active not recruiting24 enrolled
NCT04762979 2026-01-02Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast CancerBig Ten Cancer Research ConsortiumPhase 2 Active not recruiting44 enrolled